You are here:

budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART)


Following a full submission

budesonide/formoterol turbohaler (Symbicort® SMART®) is accepted for use within NHS Scotland, in adults, for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate; Symbicort is taken as regular maintenance treatment and as needed in response to symptoms.

In patients using inhaled budesonide/formoterol as preventer therapy, use of the same inhaler for reliever therapy is associated with a longer time to first severe exacerbation than use of comparator reliever regimens. In addition, some patients may be able to reduce the dose of preventer therapy.

Drug Details

Drug Name: budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART)
SMC Drug ID: 362/07
Manufacturer: AstraZeneca UK Ltd
Indication: Asthma
BNF Category:
Sub Category: 3.3 Cromoglicate and related therapy and leukotriene receptor antagonists
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 June 2007